Innoviva, Inc.
Financials
Valuation Metrics
Innoviva, Inc.'s Market Cap is $1.53B. At end of 2025 it was $1.50B. Ranked #2215 of 3,111 in US market (top 71%), #875 of 1,445 on NASDAQ (top 61%), #162 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 60%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.53B | US#2,215/3,111 Sec#162/269 |
| Revenue | $424M | US#2,430/3,111 Sec#85/269 |
| Net Income | $504M | US#810/3,111 Sec#31/269 |
| Total Assets | $1.84B | US#2,123/3,111 Sec#57/269 |
| Net Assets | $1.34B | US#1,563/3,111 Sec#49/269 |
| Employees | 159 | US#1,423/3,111 Sec#56/269 |
| Value | ||
| P/E | 3.04x | US#18/3,111 Sec#2/269 |
| P/B | 1.14x | US#499/3,111 Sec#26/269 |
| PEG | 0.00x | US#8/3,111 Sec#2/269 |
| P/S | 3.61x | US#2,001/3,111 Sec#59/269 |
| EV/EBITDA | 1.97x | US#19/3,111 Sec#2/269 |
| FCF Yield | 11.80% | US#381/3,111 Sec#14/269 |
| Profitability | ||
| ROE | 37.59% | US#181/3,111 Sec#19/269 |
| ROA | 27.46% | US#37/3,111 Sec#8/269 |
| Op. Margin | 14.85% | US#1,242/3,111 Sec#51/269 |
| Revenue Growth | 10.56% | US#1,262/3,111 Sec#92/269 |
| Earnings Growth | 1059.22% | US#43/3,111 Sec#5/269 |
| Financial Health | ||
| Debt Ratio | 36.89% | US#422/3,111 Sec#122/269 |
| Total Debt | $331M | US#2,024/3,111 Sec#71/269 |
| FCF | $181M | US#1,408/3,111 Sec#49/269 |
| Cash | $603M | US#951/3,111 Sec#48/269 |
| Current Ratio | 21.13x | US#118/3,111 Sec#32/269 |
| Net Debt/EBITDA | -0.42x | US#460/3,111 Sec#27/269 |
| Dividend | ||
| Div. Growth | -87.50% | US—/3,111 Sec—/269 |
| Performance | ||
| 1Y Return | 11.49% | US#1,557/3,111 Sec#174/269 |
| 1M Return | -6.90% | US#2,049/3,111 Sec#143/269 |
| From 52W High | -17.42% | US#1,446/3,111 Sec#96/269 |
| 1Y MDD | -23.53% | US#920/3,111 Sec#47/269 |
| Trading | ||
| Volume | 779,579 shares | US#2,256/3,111 Sec#223/269 |
| Trading Value | $16M | US#2,428/3,111 Sec#198/269 |
| Per Share | ||
| EPS | $3.63 | US#849/3,111 Sec#25/269 |
| BPS | $15.68 | US#1,453/3,111 Sec#43/269 |
Company Info
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.